Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms

Experts Meeting on Gynecologic Oncology

May 19-21, 2016 San Antonio, USA

Ingegerd Hellstrom, Yuen Yee Yip, Kathy Agnew, Karl Erik Hellstrom, Elizabeth M Swisher and John B Liao

University of Washington, USA

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

We have measured HE4 levels in urines and sera from normal donors, patients with ovarian neoplasms of low malignant potential (LMP) and ovarian cancer patients and correlated levels with clinical factors in ovarian cancer patients. Archived samples from controls, patients with LMP tumors and ovarian cancer were tested using commercial assays, as were serially collected serum and urine samples from women treated for stage III/IV serous ovarian cancer. Stage I/II and Stage III/ IV serous ovarian cancer patients had HE4-positive urines similar to serum samples when tested at the same level of specificity (95%), while urine HE4 was more sensitive from patients with LMP tumors where 28% were HE4-positive versus 4% of sera (P=0.002). Mean levels of serum CA125 and HE4 decreased comparably in patients during initial treatment regardless of their primary platinum response, but mean urine HE4 levels decreased only 7% in primary platinum resistant patients while decreasing 68% in those who were sensitive. By 7 months after diagnosis, urine HE4 levels were higher in primary platinum resistant patients compared to those who proved to be sensitive (p=0.051) and persisted 12 months after diagnosis (p=0.014). HE4 values in urine also became positive in advance of clinical recurrence in several women while serum HE4 and serum CA-125 remained normal. We conclude that measuring HE4 in urine complements serum assays for the detection of ovarian cancer and propose that a â�?�?blindedâ�? prospective study is performed on a much larger patient material and including women at increased risk for ovarian carcinoma.

Biography :

Email: ihellstr@u.washington.edu